Noncirrhotic portal hypertension (NCPH) is a rare but important clinical entity in human immunodeficiency virus (HIV) populations. The purpose of this study was to describe the clinical factors associated with the condition in an effort to formulate a diagnostic algorithm for easy and early diagnosis. We performed a multicenter, retrospective case-control study of 34 patients with NCPH and 68 control HIV patients. The study found that thrombocytopenia, splenomegaly, didanosine use, elevated aminotransferases, and an elevated alkaline phosphatase level were all significantly more prevalent in the NCPH cohort. Using these easily available clinical parameters, we developed an algorithm for early diagnosis of NCPH in HIV.
There is a growing burden of liver disease in the human immunodeficiency virus (HIV)-infected population. Noncirrhotic portal hypertension (NCPH) is a rare clinical entity, occurring in up to 0.5% of HIV patients [1] . However, NCPH has potentially catastrophic consequences, as patients often present with variceal bleeding. NCPH is characterized by sequelae of portal hypertension in the absence of liver cirrhosis, leading to significant morbidity and mortality [1, 2] . Although the underlying etiology remains unclear, exposure to certain antiretroviral drugs (ARVs), particularly didanosine (ddI), may play a pathophysiologic role [3] .
Many studies have linked NCPH with the use of ddI [3] [4] [5] . The hepatotoxicity of ddI leading to endothelial and mitochondrial damage has been implicated in triggering the NCPH cascade [4] . Hypercoagulability and microbial translocation may also play a role in the pathogenesis [4, 6, 7] . Other authors have suggested that HIV infection itself can lead to intraportal hepatic fibrosis, similar to the development of pulmonary fibrosis in HIV patients [7] .
Most reports of NCPH in HIV patients have been small retrospective studies, including many case reports. In the 2 casecontrol studies published, cirrhosis or NCPH was not excluded in the controls by either liver biopsy or transient elastography (TE) [3, 6] . It has been difficult to draw definitive conclusions on the nature of NCPH and its clinical associations from the literature to date, due to small sample sizes, suboptimally defined controls, and lack of stringent criteria in the diagnosis of NCPH.
The objective of this large case-control study was to determine clinical differences between HIV patients with and without NCPH to develop a diagnostic algorithm that could be used in clinical practice.
METHODS

Definitions of Cases and Controls
This was a collaborative effort between the Icahn School of Medicine at Mount Sinai, New York, and Kings College, London, United Kingdom, and was approved by the institutional review boards of both institutions. The cases were defined as any HIVpositive patient presenting with symptoms of portal hypertension (esophageal varices, splenomegaly, ascites, or thrombocytopenia) and without another liver disease or cirrhosis. The diagnosis of NCPH was confirmed by hepatologists experienced in treating HIV-infected patients. Controls were consecutive patients seen in the general HIV practice. All patients without liver disease or portal hypertension who agreed to undergo a TE assessment were included. Cirrhosis was excluded in cases and controls by clinical examination and histological (Metavir stage IV/IV) or noninvasive (TE score >15 kPa) modalities of fibrosis assessment. In case of discrepancy between the TE score and the biopsy, the result of the biopsy was the one retained after confirmation of the absence of cirrhosis on imaging. No controls underwent biopsy. Viral hepatitis and excessive alcohol consumption were excluded in all patients. Other liver diseases were also excluded on an individual basis when indicated by the hepatologist.
Data Collection
Laboratory values were collected as continuous values and as discrete values defined as the accepted limit of the test: alkaline phosphatase 115 U/L, total bilirubin 1.2 g/dL, direct bilirubin 0.8 g/dL, total protein 6.0 g/dL, albumin 3.5 g/dL, and platelets 150 × 10 3 /µL. For hemoglobin, a threshold of 12.0 g/dL was used for women and 13.5 g/dL was used for men. Even though the cutoff points have been recently changed for aspartate aminotransferase (AST) and alanine aminotransferase (ALT), to keep the algorithm simple, the older cutoff value of 40 U/L was used. Splenomegaly was defined clinically or on imaging (minimum length of 13 cm).
Development of the Algorithm
All variables that were significantly different between the cases and the controls were evaluated for inclusion in the algorithm. To be included in the algorithm, the variables had to be easily available clinically, relatively frequent (>50%) in the NCPH population, and relatively infrequent (<20%) in the control population. Different combinations were tested to optimize the sensitivity and the specificity of the algorithm.
Statistics
The χ 2 and Fisher exact tests were used for discrete variables.
The Student t test was used for normally distributed variables. For nonnormally distributed variables, log transformation was performed. If variables were still not normally distributed, Mann-Whitney U test was used. Sensitivity, specificity, positive and negative predictive values, and c statistic were calculated for the algorithm.
RESULTS
Thirty-four cases and 68 controls were identified. Both groups were similar in age and consisted of a predominantly white, male population (Table 1) . Both cohorts had a similar duration of HIV infection, although the NCPH group had a longer average exposure to ARVs (14.5 vs 5 years, P < .001) and a lower nadir CD4 T-cell count (150 vs 328 cells/µL, P < .001).
The NCPH cohort demonstrated a significantly larger percentage of patients (94.1% vs 14.7%, P < .001) with exposure to ddI. Among 34 cases, 2 patients died from non-liver etiology. On a continuous scale, cases had significantly lower albumin, total protein, hemoglobin, and platelets as well as greater alkaline phosphatase, AST, ALT, international normalized ratio (INR), and total and direct bilirubins (Table 1) . When analyzed as categorical variables, INR, total bilirubin, and direct bilirubin did not remain significant. Even if statistically significant, the absolute number of patients with abnormal values for albumin and total protein was small. ALT (46.2% vs 22.4%, P = .01) and hemoglobin (69.7% vs 22.1%, P < .001) levels also remained significant, but the number of controls with an abnormal value was >20% in both cases. Platelets (81.8% vs 13.2%, P < .001), alkaline phosphatase (55.9% vs 7.5%, P < .001), and AST (65.6% vs 13.2%, P < .001) fulfilled our criteria for inclusion in the algorithm.
As expected, as it was part of our case definition, the NCPH cohort had a significantly higher rate of esophageal varices, esophageal variceal bleeding (EVB), splenomegaly, and ascites compared to the control group.
TE was performed in 59% of the cases and all the controls. The mean TE scores of the NCPH group were significantly more elevated (9.0 vs 4.9, P < .001). The TE score was >10 kPa in 45.0% of cases vs 2.9% of controls (P < .001). The most common biopsy was hepatoportal sclerosis (12/28 [42.9%]), followed by nodular regenerative hyperplasia (11/28 [39.3%]), with 60.7% (17/28) of the biopsies demonstrating at least 1 of these findings.
The algorithm is presented in Figure 1 . Discrete variables were favored over continuous variables to keep the algorithm simple. Biopsy, TE, and endoscopy were not considered as they are not easily available as screening tools. The finalized algorithm included thrombocytopenia, splenomegaly, ddI exposure, AST, and alkaline phosphatase, leading to a sensitivity of 97.1% and a specificity of 92.6%. The negative predictive value was 98.4% and the positive predictive value was 86.8%. The area under the receiver operating characteristic curve of the algorithm was 0.949 (95% confidence interval, .899-.998).
DISCUSSION
The association between NCPH and HIV is relatively recent, and diagnostic criteria for NCPH are still not established in the literature. A recent case series defined NCPH as elevated transaminases for 1 year, but 40% of these patients were found to have cirrhosis [4] .
Of our 34 NCPH patients, more than half (55.9%) presented with EVB, demonstrating that NCPH in HIV patients is underdiagnosed, perhaps due to the lack of a screening algorithm for HIV providers. Almost 90% of the cases were also found to have esophageal varices, which is higher than prior studies (15%-69%) [1, 4, [7] [8] [9] . It is important that subtle clinical findings that are prominent in these patients are identified early by HIV clinicians to avoid catastrophic presentations such as EVB.
In our study, the majority of NCPH patients had splenomegaly, thrombocytopenia, and elevated alkaline phosphatase compared to the controls. This has also been described by Kovari et al [3] . AST and ALT were also elevated, 2 findings seen in prior studies [3, 6] . Despite the presinusoidal nature of NCPH, 42.9% of our cohort had ascites [10] . Although ascites is more commonly associated with postsinusoidal portal hypertension, the increased capillary hydrostatic pressure that results in ascites is also seen in presinusoidal portal hypertension. Ascites was seen in 18%-53% of NCPH patients in prior studies [3, 6] . Our NCPH cohort reported a longer exposure to ARV therapy. Drug hepatotoxicity as a possible etiology of NCPH has been hypothesized by several authors, and our findings support this hypothesis [3, 11] . Didanosine is the specific ARV medication most frequently associated with NCPH. Ninety-four percent of our cases were positive for ddI exposure. Kovari et al demonstrated similar findings in terms of ddI exposure and duration in their NCPH cases [3] .
This was the first study to compare TE scores between NCPH cases and controls. TE measures liver elasticity and is a surrogate marker of liver fibrosis. TE scores were significantly greater in the NCPH population (9.0 kPa vs 4.9 kPa, P < .001). Prior NCPH case series have found average TE scores of 8.1-9.9 kPa [7, 9, 12] , which correlate with moderate hepatic fibrosis (Metavir stage 2-3) [13] . However, biopsy results do not necessarily correlate with such a degree of fibrosis. In our study and a in literature review performed by Cesari et al, nodular regenerative hyperplasia and hepatoportal sclerosis were the 2 most common biopsy findings in patients with NCPH [6] . TE may exaggerate the extent of fibrosis in NCPH patients [6, 9] . Despite this potential error, NCPH patients usually have TE scores that are above normal but well below the cutoff for cirrhosis (15 kPa). This fact, combined with the fact that there is a significant difference in TE scores between NCPH patients and HIV controls, strongly suggests that there is diagnostic utility for TE in NCPH.
Despite the usefulness of liver biopsy in the diagnosis of NCPH, its invasive nature limits its use as a screening tool. A diagnostic algorithm that can help HIV providers in selecting appropriate patients for NCPH evaluation before the sentinel clinical manifestations of portal hypertension is necessary. Based on the significant prevalence of factors in our study, we proposed a diagnostic flowchart (Figure 1 ). Only clinical variables that were easily obtainable were included in an effort to make the algorithm readily applicable.
Didanosine exposure or splenomegaly in an HIV-infected individual with no known liver disease should trigger evaluation for NCPH. Absence of liver disease should be confirmed by hepatitis serology as well as an alcohol intake form. Patients who meet these entry criteria should then be assessed for thrombocytopenia, AST >40 U/L, or an alkaline phosphatase level >115 U/L. If the patient meets any of these second-level criteria, he or she should be referred to a liver specialist. The hepatologist can pursue a more confirmatory workup to definitively rule out cirrhosis and diagnose NCPH, such as transient elastography or liver biopsy. The hepatologist can also opt to perform endoscopic evaluation for varices.
Our study has some limitations. NCPH is a rare disease and a retrospective design is difficult to avoid. In that context, the large number of cases and the use of TE are important strengths of this study. All of our controls underwent TE and, therefore, unlike the prior case-control studies, significant underlying fibrosis was excluded. All 34 NCPH patients underwent a liver biopsy or TE. Moreover, all patients with TE scores >10 kPa had a corresponding liver biopsy to ensure the absence of cirrhosis, demonstrating optimal fibrosis assessment. Because TE assessment is not done on a regular basis in HIV-infected patients without liver disease, controls had to be recruited on a prospective basis and may temporarily differ from the retrospectively collected cases. Nevertheless, controls came from a regular HIV practice and should reflect the population to which the algorithm will be applied.
Even if the algorithm demonstrated good sensitivity, specificity, and negative and positive predictive values in our population, its external validity has not been assessed. Ideally, this should be done on a prospective basis. Its main strength lies in its easy applicability in clinical practice. This is the largest series of NCPH patients reported to date. Although NCPH is a rare disease, the majority of these patients present with life-threatening EVB. We propose a diagnostic algorithm, based on easily available clinical parameters, to identify NCPH in HIV patients. Early evaluation by a liver specialist for HIV patients with suspected NCPH is recommended.
